GLP-1 / GIP Agonists
Tirzepatide 30mg
A dual GLP-1 and GIP receptor agonist studied for metabolic regulation and glucose homeostasis.
Form
Lyophilized Powder
Quantity
30mg per vial
Purity
>99% (HPLC)
Sequence
39aa GLP-1/GIP agonist
MW
4,813 g/mol
Storage
-20°C (lyophilized)
Batch Verification
Purity (HPLC)
>99%
Batch ID
VX-TIRZ30-001
MW Confirmed
LC-MS
Endotoxin
<0.1 EU/mg
Independently verified by Janoshik: HPLC Purity + LC-MS Identity + LAL Endotoxin
Research Applications
Tirzepatide is a 39-amino-acid peptide that activates both GLP-1 and GIP receptors. Research investigates dual-incretin action on insulin secretion, appetite regulation, and energy expenditure.
Research indicates Tirzepatide activates incretin pathways through GLP-1 and GIP receptor engagement. Studies focus on glucose-dependent insulin secretion, satiety signaling, and metabolic research.
Research Use Only
This product is intended for laboratory research use only. Not for human consumption or clinical use. Not FDA approved for diagnostic or therapeutic purposes.
This product is intended for laboratory research use only. Not for human consumption or clinical use. Not FDA approved for diagnostic or therapeutic purposes.